Skip to content

Performance Evaluation of Artificial Intelligence Screening Model in Coronary Heart Disease Detection

Performance Evaluation of Artificial Intelligence Screening Model in Coronary Heart Disease Detection

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06658600
Acronym
DeepCHD
Enrollment
900
Registered
2024-10-26
Start date
2025-01-10
Completion date
2025-05-31
Last updated
2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Keywords

obstructive coronary heart disease, retinal images, artificial intelligence

Brief summary

To determine whether an integrated AI decision support can save time and improve accuracy of assessment of obstructive coronary heart disease (CHD), the investigators are conducting a randomized controlled study of AI guided measurements of obstructive CHD probability compared to clinical assessment in preliminary evaluations by physicians.

Detailed description

This is a randomized controlled trial (RCT) evaluating the effectiveness of an AI-based decision support tool in the preliminary assessment of obstructive CHD by physicians. Retrospectively collected medical records of participants with chest pain or dyspnea will be randomly assigned to either guideline group or AI group after baseline assessment: There are three settings: 1. Clinical Intuition (baseline assessment) Physicians assess obstructive CHD probability without any external assistance. Assessment relies solely on the physician's clinical judgment and experience. 2. Guideline-Based Group (Guideline Group) Physicians use a RF-CL table (risk factor weighted clinical likelihood table) to calculate the probability of obstructive CHD. This approach aligns with current clinical guidelines to assist in decision-making. 3. AI-Assisted Group (AI Group) Physicians receive CHD probability estimates and diagnostic recommendations from an AI model based on retinal photographs. The AI tool provides individualized obstructive CHD probabilities, leveraging retinal biomarkers associated with cardiovascular risk. Primary Objective To evaluate whether AI-guided decision support could improves diagnostic accuracy of obstructive CHD to a greater extent than standard clinical assessments, both compared to clinical intuition. Secondary Objective To assess whether AI-guided decision support reduces the time required to complete preliminary assessments of obstructive CHD. Participants, Readers and Randomization Participants: Case records of participants with chest pain or dyspnea, all underwent CT coronary angiography or invasive coronary angiography. Readers: Physicians performing preliminary evaluations of obstructive CHD patients. Randomization: Participants and readers will be randomized into one of the groups (RF-CL or AI) after clinical assessment at baseline using block randomization to ensure balanced group sizes.

Interventions

OTHERPhysician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease

Physician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease. The AI tool provides individualized obstructive CHD probabilities and diagnosis, leveraging retinal biomarkers associated with cardiovascular risk.

OTHERPhysician readers will be assisted with RF-CL table to calculate the probability of obstructive coronary heart disease

Physicians use a RF-CL table (risk factor weighted clinical likelihood table) to calculate the probability of obstructive CHD.

Sponsors

Shanghai Jiao Tong University Affiliated Sixth People's Hospital
CollaboratorOTHER
Shanghai Health and Medical Center
CollaboratorUNKNOWN
Tsinghua University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Individuals with symptoms of coronary heart disease * Age range: 18-75 years old * Can accept and cooperate with the examination and potential follow-up work after being selected for clinical trials

Exclusion criteria

* Severe hypertension (\>180/110mmHg) * Complex arrhythmia (atrial fibrillation, atrial flutter, frequent premature beats) * Severe lung disease and chest malformation or surgery patients * Acute myocardial infarction occurring less than 3 months ago * Individuals with severe liver and kidney dysfunction and electrolyte imbalance

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic Accuracy of Participants with Obstructive Coronary Heart DiseaseThrough study completion, an average of 1 weekWhether AI-guided decision support improves the diagnostic accuracy of obstructive coronary heart disease (CHD) to a greater extent than standard clinical assessments (RF-CL), both compared to clinical intuition. All participants of the case records had underwent CT angiography or invasive angiography. The diagnostic accuracy, sensitivity and specificity will be compared across groups.

Secondary

MeasureTime frameDescription
Time Consumed by Physician Readers to Provide the Diagnosis Impression of Obstructive Coronary Heart Disease.Through study completion, an average of 1 weekThe time consumed by physician readers will be recorded by an algorithm implemented on the website for reading.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026